【摘要】：目的評(píng)價(jià)嘉興市第一醫(yī)院慢性乙型肝炎住院患者保肝藥的用藥情況及合理性,為臨床合理用藥提供參考。方法采用藥物利用評(píng)價(jià)(DUR)和藥物利用評(píng)估(DUE)法,對(duì)該院慢性乙型肝炎住院患者使用保肝藥的藥物利用指數(shù)(DUI)、藥物應(yīng)用情況、治療過程監(jiān)測(cè)及臨床治療效果進(jìn)行分析。結(jié)果 97例患者共使用保肝藥17個(gè)品種、21個(gè)品規(guī),用藥頻度前3位的藥物分別為多烯磷脂酰膽堿注射液、注射用丁二磺酸腺苷蛋氨酸和注射用復(fù)方甘草酸苷。5個(gè)品規(guī)藥物的DUI1,13個(gè)品規(guī)的DUI=1,3個(gè)品規(guī)的DUI1。一聯(lián)、二聯(lián)、三聯(lián)和四聯(lián)用藥的構(gòu)成比分別為30.93%(30/97)、46.39%(45/97)、17.53%(17/97)和5.15%(5/97),對(duì)應(yīng)患者肝功能恢復(fù)或好轉(zhuǎn)構(gòu)成比依次為70.00%(21/30)、91.11%(41/45)、82.35%(14/17)和60.00%(3/5)。研究對(duì)象均符合病原學(xué)分型及臨床分期,僅3.09%(3/97)的病例確定了病理學(xué)分期。97例患者均有肝功能異�，F(xiàn)象,肝功能監(jiān)測(cè)率達(dá)100.00%(97/97),93例患者經(jīng)抗炎保肝等治療后臨床癥狀得到改善,79例患者肝功能恢復(fù)正常。結(jié)論聯(lián)合DUR和DUE法可以更全面地評(píng)價(jià)慢性乙型肝炎患者的用藥情況。該院慢性乙型肝炎住院患者保肝藥用藥基本合理,二聯(lián)用藥保肝治療效果最好。
[Abstract]:Objective to evaluate the usage and rationality of liver protective drugs in patients with chronic hepatitis B (CHB) in Jiaxing first Hospital, and to provide reference for rational use of drugs in clinic. Methods Drug utilization evaluation (DUR) and drug utilization assessment (DUE) were used to evaluate the drug utilization index (DUI),) of patients with chronic hepatitis B in our hospital. The therapeutic process monitoring and clinical treatment effect were analyzed. Results in 97 patients, 17 kinds of hepatoprotective drugs were used, 21 drugs were used, and the top 3 drugs were polyenylphosphatidylcholine injection. Adenosylmethionine butyldisulfonic acid for injection and compound glycyrrhizin for injection. DUI1, of 5 drugs, DUI=1, of 13 products and DUI1. of 3 products The constituent ratios of one, two, three and four drugs were 30.93% (30 / 97), 46.39% (45 / 97), 17.53% (17 / 97) and 5.15% (5 / 97), respectively. The proportion of recovery or improvement of liver function was 70.00% (21 / 30), 91.11% (41 / 45), 82.35% (14 / 17) and 60.00% (3 / 5) respectively. The pathological staging was confirmed in only 3.09% (3 / 97) of the patients. The abnormal liver function was found in 97 patients, and the monitoring rate of liver function was 100.00% (97 / 97). The clinical symptoms of 93 patients were improved after anti-inflammatory therapy and liver preservation therapy, and 79 patients returned to normal liver function. Conclusion the combination of DUR and DUE can more comprehensively evaluate the drug use in patients with chronic hepatitis B. The liver protection drugs used in the inpatients with chronic hepatitis B in our hospital were basically reasonable, and the combined therapy was the best.
【作者單位】： 嘉興市第一醫(yī)院藥學(xué)部;嘉興市第一醫(yī)院感染科;
【基金】：浙江省藥學(xué)會(huì)醫(yī)院藥學(xué)專項(xiàng)科研資助項(xiàng)目(2014-ZYY29)
【分類號(hào)】：R512.62

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 鄒豪，陳盛新;藥物利用評(píng)價(jià)的內(nèi)涵及方法[J];藥學(xué)實(shí)踐雜志;1996年05期

2 賴琪,胡明,蒲劍,吳蓬;藥物利用評(píng)價(jià)與醫(yī)院質(zhì)量保證[J];中國藥師;2001年06期

3 劉喜軍,魏水易;藥物利用評(píng)價(jià)的現(xiàn)狀與發(fā)展趨勢(shì)[J];中國醫(yī)院用藥評(píng)價(jià)與分析;2003年06期

4 吳廷s，

本文編號(hào)：2316413